Results 181 to 190 of about 2,077,052 (339)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Genetic evaluation of growth rate and efficiency-related traits in Menz sheep. [PDF]

PLoS One
Bisrat A, Besufkad S, Abebe A, Goshme S, Abebe A, Zewdie T, Areaya A, Tesema Z, Demis C, Yitagesu E, Wondifra Y, Asfaw T, Alemnew E, Gizaw S, Getachew T, Rischkowsky B, Rekik M, Belay B, Haile A.   +18 more
europepmc   +1 more source

Molecular taxonomic characterization of the human parasitic population of the nematode Strongyloides stercoralis in Cambodia and development and evaluation of methods for the genetic study of Strongyloides ratti

, 2016
Guo Li
openalex   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Mild RPE65-Associated Inherited Retinal Dystrophies: A Multimodal Clinical and Genetic Evaluation. [PDF]

Transl Vis Sci Technol
Wolfram L, Merle DA, Kühlewein L, Kempf M, Stingl K, Kohl S, Stingl K.   +6 more
europepmc   +1 more source

Evaluating Adults With Idiopathic Pancreatitis for Genetic Predisposition

, 2014
Darren D. Ballard, Joyce Flueckiger, Evan L. Fogel, Lee McHenry, Glen A. Lehman, James L. Watkins, Stuart Sherman, Gregory A. Coté   +7 more
openalex   +1 more source

A phase I clinical study to evaluate safety of orally administered, genetically engineeredSalmonella entericaserovarTyphimuriumfor canine osteosarcoma [PDF]

, 2016
Sara E. Fritz, Michael S. Henson, Emily Greengard, Amber L. Winter, Kathleen Stuebner, Una Yoon, Vicki L. Wilk, Antonella Borgatti, Lance B. Augustin, Jaime F. Modiano, Daniel A. Saltzman   +10 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Genetic evaluation of early-onset atrial fibrillation: impact on patient management. [PDF]

Eur Heart J
Laws JL, Shabani M, Williams HL, Grauherr DD, Kilbourne WM, Crawford DM, Ogunmola I, Sun L, Virk Z, Cathey B, El-Harasis MA, Pelphrey CJ, Quintana JA, Murphy BS, Davogustto GE, Ponder ME, Irani OM, Daw JM, Varghese BT, Saavedra P, Abraham RL, Estrada JC, Murray KT, Clair WK, Shen ST, Kanagasundram AN, Montgomery JA, Ellis CR, Fish F, Richardson TD, Crossley GH, Hung RR, Dendy JM, Wright A, Wells QS, Ye F, Tandri H, Stevenson WG, Lancaster M, Kannankeril PJ, Stevenson LW, Roden DM, Yoneda ZT, Shoemaker MB.   +43 more
europepmc   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source